A Description of Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns Including Initiation, Switching, and Discontinuation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 615,067
- 试验地点
- 1
- 主要终点
- Treatment Augmentation for MarketScan Patients
研究概览
简要总结
This protocol is for a series of descriptive analyses conducted within a cohort of patients using linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, and other oral and non-insulin injected hypoglycemic medications between May 2011 and July 2012.
Understanding 1) the existing utilization patterns for linagliptin, sitagliptin, saxagliptin, and other oral and non-insulin injected hypoglycemic agents and (2) the differences in utilization patterns between these agents will help with the design, analysis and interpretation of comparative effectiveness and safety studies of linagliptin, other DPP-4 inhibitors, and other agents.
The study will provide an overview of existing utilization patterns for linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, other oral and non-insulin injected hypoglycemic agents, in order to detect potential selective prescribing patterns that might lead to channeling bias.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Treatment Augmentation for MarketScan Patients
时间窗: up to 12 months
Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy
Subsequent Insulin Initiation for United Healthcare Patients
时间窗: up to 12 months
Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months
Treatment Switching for United Healthcare Patients
时间窗: up to 12 months
Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days
Treatment Switching for MarketScan Patients
时间窗: up to 12 months
Number of patients with dispensing of a new non-insulin hypoglycemic agent without subsequent to the end of days' supply of the original agent plus 30 days
Treatment Augmentation for United Healthcare Patients
时间窗: up to 12 months
Number of patients dispensing of a new non-insulin hypoglycemic agent while continuing to fill prescriptions for the initial therapy
Subsequent Insulin Initiation for MarketScan Patients
时间窗: up to 12 months
Number of patients filling an insulin prescription subsequently to initiation of the original non-insulin agent without having filled one in the past 6 months
Proportion of Initiators for United Healthcare Patients
时间窗: up to 12 months
Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.
Proportion of Initiators for MarketScan Patients
时间窗: up to 12 months
Number of patients initiating each individual agent divided by the number of patients initiating any oral or non-insulin injected hypoglycemic agent.
次要结局
- Persistence at 6 Months for United Healthcare Patients(6 months)
- Treatment Discontinuation for United Healthcare Patients(up to 12 months)
- Proportion of Days Covered for United Healthcare Patients(up to 12 months)
- Persistence at 3 Months for United Healthcare Patients(3 months)
- Persistence at 3 Months for MarketScan Patients(3 months)
- Treatment Discontinuation for Marketscan Patients(up to 12 months)
- Proportion of Days Covered for MarketScan Patients(up to 12 months)
- Persistence at 12 Months for United Healthcare Patients(12 months)
- Persistence at 12 Months for MarketScan Patients(12 months)
- Persistence at 6 Months for MarketScan Patients(6 months)